- Home
- MTVA vs SYNX Comparison
MTVA vs SYNX Comparison
Compare MTVA & SYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTVA
- SYNX
- Stock Information
- Founded
- MTVA 2014
- SYNX 2005
- Country
- MTVA United States
- SYNX Israel
- Employees
- MTVA N/A
- SYNX N/A
- Industry
- MTVA
- SYNX
- Sector
- MTVA
- SYNX
- Exchange
- MTVA NYSE
- SYNX Nasdaq
- Market Cap
- MTVA 16.8M
- SYNX 18.5M
- IPO Year
- MTVA N/A
- SYNX 2024
- Fundamental
- Price
- MTVA $1.74
- SYNX $3.89
- Analyst Decision
- MTVA Strong Buy
- SYNX
- Analyst Count
- MTVA 1
- SYNX 0
- Target Price
- MTVA $12.00
- SYNX N/A
- AVG Volume (30 Days)
- MTVA 57.9K
- SYNX 61.6K
- Earning Date
- MTVA 03-27-2025
- SYNX 10-02-2024
- Dividend Yield
- MTVA N/A
- SYNX N/A
- EPS Growth
- MTVA N/A
- SYNX N/A
- EPS
- MTVA N/A
- SYNX N/A
- Revenue
- MTVA N/A
- SYNX $9,893,000.00
- Revenue This Year
- MTVA N/A
- SYNX $52.34
- Revenue Next Year
- MTVA N/A
- SYNX N/A
- P/E Ratio
- MTVA N/A
- SYNX N/A
- Revenue Growth
- MTVA N/A
- SYNX 18.05
- 52 Week Low
- MTVA $1.51
- SYNX $2.10
- 52 Week High
- MTVA $6.75
- SYNX $6.49
- Technical
- Relative Strength Index (RSI)
- MTVA N/A
- SYNX 46.13
- Support Level
- MTVA N/A
- SYNX $3.91
- Resistance Level
- MTVA N/A
- SYNX $4.39
- Average True Range (ATR)
- MTVA 0.00
- SYNX 0.35
- MACD
- MTVA 0.00
- SYNX -0.09
- Stochastic Oscillator
- MTVA 0.00
- SYNX 2.25
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
About SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat-proven. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both in training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, market and sell push-to-talk devices, communication controllers, and communication device cables and connectors.